Irvine – October 29, 2026 -- SBC Medical Group Holdings (Nasdaq: SBC) has begun in-house development of a DNA methylation test to estimate biological age, entering a longevity market that Report Ocean projects will grow from about $800 billion in 2025 to about $2 trillion by 2035.
SBC AI Longevity Innovation leads development on the Waqoo Group research base
The Medical Services Organization has assigned the project to its subsidiary SBC AI Longevity Innovation, Inc. The unit will draw on the regenerative medicine research of Waqoo, Inc. (TSE: 4937), a consolidated SBC Medical subsidiary, and Waqoo's subsidiary Cell Pro Japan Co., Ltd.
SBC Medical will pair that molecular research with its clinic operations infrastructure and customer experience know-how from its core MSO business. The company says objective, repeatable ways to track the body's internal condition over time remain limited.
Epigenetic markers that change with lifestyle drive the test design
Unlike the genetic code, DNA methylation can shift with environment, diet, stress and lifestyle. SBC Medical therefore plans to measure biological age before and after lifestyle changes, creating a feedback loop rather than a one-off metric.
The science has advanced since the first epigenetic clock methodology was published in 2013. In 2025, researchers showed a method to estimate the ages of 11 physiological systems from a single blood draw, according to a Nature Aging paper cited by the company.
Three pillars define the development roadmap
- Organ-specific mapping: assessing biological age by organ system to locate where aging-related changes are progressing.
- Non-invasive modalities: researching consumer-friendly measurement methods that need no blood draw.
- Japan-specific data: building an evaluation framework from Japanese cohorts.
The company describes the information as based on current plans and subject to change. It has not disclosed a launch date, pricing or development budget.